Welcome to the international HTA database

Showing [21342 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Reinforced foster homes]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Alternative methods to coercive measures]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Diagnostic precision with liquid biopsy for asymptomatic ovarian cancer]
2024	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Post covid and other post infectious diseases]
2024	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Indicated prevention of suicide in children and adolescents]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024	Norwegian Institute of Public Health (NIPH)	[Robot-assisted prostatectomy for prostate cancer]
2024	Norwegian Institute of Public Health (NIPH)	[Robot-assisted rectal resection for rectal cancer]
2024	Norwegian Institute of Public Health (NIPH)	[Robotic hysterectomy]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2023	Canary Health Service	[Cost-effectiveness of newborn screening for tyrosinemia type I (update)]
2023	NIHR Health Services and Delivery Research programme	Remote monitoring for long-term physical health conditions: an evidence and gap map
2023	NIHR Health Services and Delivery Research programme	What factors are associated with informal carers’ psychological morbidity during end-of-life home care? A systematic review and thematic synthesis of observational quantitative studies
2023	NIHR Health Technology Assessment programme	One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic-laden bone cement
2023	NIHR Health Technology Assessment programme	Pragmatic randomised controlled trial of guided self-help versus individual cognitive behavioural therapy with a trauma focus for post-traumatic stress disorder (RAPID)
2023	NIHR Health Technology Assessment programme	Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit–risk assessment: the BRAINS study including expert workshop
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Medication review and reconciliation in the outpatient setting
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2023	Canary Health Service	[Evaluation of the lung cancer screening program]
2023	Canary Health Service	[Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies]
2023	Canary Health Service	[Effectiveness and safety of bioelectrical stimulation techniques in fibromyalgia: systematic review]
2023	Canary Health Service	[Evaluation of patient involvement in health technology assessment]
2023	Norwegian Institute of Public Health (NIPH)	[Mupirocin nasal ointment as infection prevention prophylaxis prior to orthopaedic prosthesis surgery: a rapid health technology assessment]
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Biologic drugs for severe asthma
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Routine dental polishing for oral health
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intraocular lenses for cataract surgery
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Refractive laser surgery for vision conditions
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Buprenorphine naloxone film versus tablets for opioid use disorder
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Case carts in surgical settings
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Anti–vascular endothelial growth factor drugs for age-related macular degeneration
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care ultrasound for guided central venous catheter insertion
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	IV acetaminophen for acute pain in emergency departments
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Semaglutide 2 mg for type 2 diabetes
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Midline and extended dwell catheters for IV antibiotics
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Radiofrequency ablation for chronic knee, hip, and shoulder pain
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Direct-acting antivirals for pediatric chronic hepatitis C virus infection
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Somatropin for short stature
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-sterile glove use
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Early intervention programs for adolescents and young adults with eating disorders
2023	Canary Health Service	[Software applications for prevention and intervention in people at risk of suicide: effectiveness, safety and cost-effectiveness]
2023	NIHR Health Services and Delivery Research programme	The effectiveness of sexual assault referral centres with regard to mental health and substance use: a national mixed-methods study – the MiMoS Study
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Embolization vs. conservative management for spontaneous abdominal or pelvic hemorrhage
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effective analysis evaluation of galcanezumab (Emgality)]
2023	NIHR Health Services and Delivery Research programme	Eye donation from palliative and hospice care contexts: the EDiPPPP mixed-methods study
2023	NIHR Health Technology Assessment programme	A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
2023	NIHR Health Technology Assessment programme	Exercise therapy for tendinopathy: a mixed-methods evidence synthesis exploring feasibility, acceptability and effectiveness
2023	NIHR Health Technology Assessment programme	Posterior cervical foraminotomy versus anterior cervical discectomy for cervical brachialgia: the FORVAD RCT
2023	NIHR Health and Social Care Delivery Program	Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT
2023	NIHR Health Technology Assessment programme	Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	NIHR Health Technology Assessment programme	Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study
2023	NIHR Health Technology Assessment programme	Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation
2023	NIHR Health Services and Delivery Research programme	Rapid evaluation of the Special Measures for Quality and challenged provider regimes: a mixed-methods study
2023	Norwegian Institute of Public Health (NIPH)	[Portable ECG equipment for the diagnosis of atrial fibrillation in the specialist health care: rapid HTA - scoping review]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[PICC line insertion by navigation system and confirmation of the catheter tip by intracavitary electrocardiogram]
2023	NIHR Health Services and Delivery Research programme	Reducing unplanned hospital admissions from care homes: a systematic review
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Emergency department overcrowding in Canada: an update
2023	Health Information and Quality Authority (HIQA)	Overview of multiplex antigen near-patient tests for acute respiratory infections
2023	NIHR Health Services and Delivery Research programme	Involving carer advisors in evidence synthesis to improve carers’ mental health during end-of-life home care: co-production during COVID-19 remote working
2023	Health Sciences Institute in Aragon (IACS)	[Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: gene panel for the identification of myeloid mutations by NGS ‒ evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “Depression”]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “Coronary heart disease”]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma in adolescents, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection for valoctocogene roxaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A22-20]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (non-transfusion-dependent beta-thalassaemia) - Addendum to Commission A23-20]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Addendum to Commission A23-21]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (prurigo nodularis) – Addendum to Project A23-24]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 \| A23-31]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fidanacogene elaparvovec (haemophilia B); assessment according to §35a Social Code Book (SGB) V; search for disease registries]